While antibody mediated depletion of CCR8+ Tregs via antibody dependent cell cytotoxicity (ADCC) can ameliorate the tumor burden, blocking CCR8 activity using antibodies that are devoid of ADCC capabilities doesn’t seem to create the same effect (52). This evidence concerns the gene CCR8 and neoplasm.